---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-206247"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:00:32.893051+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials

## Summary
- Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.
- Cash, equivalents and marketable securities $608.1M, down $38.6M from Dec 2022.
- Phase 3 SUNRISE-3 trial amended: eligibility broadened, target enrollment ~2,200; topline expected mid-2024.
- Phase 2 HCV study of bemnifosbuvir+ruzavir dosing; initial data from lead-in cohort (~60 pts) expected 4Q23.
- R&D expenses rose to $22.1M from $19.9M YoY, driven by trial costs.

## SEC filing metadata
- accession: 0001193125-23-206247
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/0001193125-23-206247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/d534379d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-206247
- JSON: https://secwatch.observer/filing/0001193125-23-206247.json
- Plain text: https://secwatch.observer/filing/0001193125-23-206247.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended June 30, 2023 and other matters described in the press release.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/0001193125-23-206247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.